About
Immatics develops T-cell receptor (TCR)-based cellular therapies and cancer vaccines targeting tumor-specific antigens such as PRAME to treat multiple types of cancer.
Explore Immatics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.